期刊文献+
共找到4,438篇文章
< 1 2 222 >
每页显示 20 50 100
尿毒症血液透析患者血红蛋白变化趋势与rHuEPO剂量的关系
1
作者 唐能源 苟晓燕 +1 位作者 邓舜天 李琦晖 《检验医学与临床》 CAS 2024年第2期225-227,231,共4页
目的分析尿毒症血液透析患者血红蛋白变化趋势与重组人促红细胞生成素(rHuEPO)剂量的关系。方法回顾性选取2021年12月至2022年10月该院门诊规律血液透析尿毒症患者73例作为研究对象,每周血液透析3次,每次4 h(包括每个月3~4次血液透析滤... 目的分析尿毒症血液透析患者血红蛋白变化趋势与重组人促红细胞生成素(rHuEPO)剂量的关系。方法回顾性选取2021年12月至2022年10月该院门诊规律血液透析尿毒症患者73例作为研究对象,每周血液透析3次,每次4 h(包括每个月3~4次血液透析滤过+每个月血液灌流2 h),记录患者rHuEPO剂量,治疗时间为2个月,根据治疗2个月后血红蛋白水平变化趋势设定为上升组(35例)和下降组(38例)。结果上升组治疗2个月后血红蛋白水平较治疗前升高,下降组治疗2个月后血红蛋白水平较治疗前降低,差异均有统计学意义(P<0.05);上升组rHuEPO使用剂量高于下降组,差异有统计学意义(P<0.05)。受试者工作特征曲线分析结果显示,rHuEPO最佳截断值为175.82 IU/(kg·w)时,诊断血红蛋白水平疗效的曲线下面积为0.684,灵敏度为82.9%,特异度为47.4%。结论规律血液透析的尿毒症患者血红蛋白水平升高与rHuEPO使用剂量有关,足量rHuEPO能使大多数患者血红蛋白水平呈上升趋势。 展开更多
关键词 血液透析 尿毒症 重组人促红细胞生成素 血红蛋白 变化趋势
下载PDF
罗沙司他与大剂量rHuEPO治疗腹膜透析肾性贫血患者的效果及安全性
2
作者 刘玉 王稻 +2 位作者 曹珊 陈清萍 廖雯 《中国医学创新》 CAS 2024年第12期14-17,共4页
目的:探讨罗沙司他与大剂量重组人促红素(rHuEPO)治疗腹膜透析肾性贫血患者的效果及安全性。方法:选择萍乡市人民医院2022年7—12月收治的60例腹膜透析肾性贫血患者进行本次研究,按照随机数字表法分为两组,各30例。对照组采用大剂量rHu... 目的:探讨罗沙司他与大剂量重组人促红素(rHuEPO)治疗腹膜透析肾性贫血患者的效果及安全性。方法:选择萍乡市人民医院2022年7—12月收治的60例腹膜透析肾性贫血患者进行本次研究,按照随机数字表法分为两组,各30例。对照组采用大剂量rHuEPO治疗,研究组采用大剂量rHuEPO联合罗沙司他治疗。对比两组疗效和治疗前后肾功能指标[血尿素氮(BUN)、血肌酐(Scr)、β_(2)-微球蛋白(β_(2)-MG)]、血液营养指标[血红蛋白(Hb)、红细胞压积(HCT)、红细胞(RBC)计数]、甲状旁腺激素(PTH)、铁代谢指标[血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)]及不良反应。结果:治疗后,研究组总有效率为90.00%,显著高于对照组的63.33%,差异有统计学意义(P<0.05);治疗后,研究组Hb、HCT、RBC均显著高于对照组,PTH显著低于对照组,差异均有统计学意义(P<0.05);治疗后,研究组SF、TSAT均显著高于对照组(P<0.05);治疗后,研究组BUN、Scr、β_(2)-MG均显著低于对照组,差异均有统计学意义(P<0.05)。结论:罗沙司他联合大剂量rHuEPO治疗可有效改善腹膜透析肾性贫血患者的贫血情况,纠正铁代谢,且不良反应少。 展开更多
关键词 腹膜透析 肾性贫血 罗沙司他 重组人促红素 安全性
下载PDF
基于HIF-1α-VEGF-EPO信号通路探究电针干预大脑中动脉栓塞大鼠脑血管新生的机制
3
作者 王玉 刘芳 +3 位作者 姚晓雯 高云云 宋宗胜 唐巍 《安徽中医药大学学报》 CAS 2024年第1期51-56,共6页
目的基于低氧诱导因子(hypoxia inducible factor,HIF)-1α-血管内皮生长因子(vascular endothelial growth factor,VEGF)-促红细胞生成素(erythropoietin,EPO)通路探究电针“百会”“水沟”“足三里”“曲池”治疗脑缺血的作用机制。... 目的基于低氧诱导因子(hypoxia inducible factor,HIF)-1α-血管内皮生长因子(vascular endothelial growth factor,VEGF)-促红细胞生成素(erythropoietin,EPO)通路探究电针“百会”“水沟”“足三里”“曲池”治疗脑缺血的作用机制。方法将108只SD雄性大鼠随机分为假手术组、模型组、电针组。采用线栓法复制右侧大脑中动脉栓塞(middle cerebral artery occlusion,MCAO)大鼠模型。电针组于模型复制后4 h电针“百会”“水沟”和左侧“后三里”(“足三里”)、“曲池”,疏密波,频率5~100 Hz,每次20 min,每日1次,治疗14 d。假手术组、模型组同等抓取固定,不进行治疗。采用改良神经功能缺损体征评分(modified neurological severity scores,mNSS)评价大鼠神经功能损害情况,多普勒超声检测缺血半暗带区局部脑血流量(regional cerebral blood flow,rCBF)变化,HE染色观察脑缺血半暗带病理学改变,免疫组织化学法检测缺血半暗带区皮质CD34阳性细胞数,Western blot法和RT-PCR法分别检测缺血半暗带区皮质HIF-1α、VEGF、EPO蛋白及其mRNA表达水平。结果与同时点假手术组比较,模型组大鼠mNSS、CD34阳性细胞数、HIF-1α、VEGF、EPO蛋白和mRNA表达水平均显著增加(P<0.05),rCBF显著减少(P<0.05),HE染色可见大量神经元坏死;与同时点模型组比较,电针组大鼠mNSS评分显著减少(P<0.05),rCBF、CD34阳性细胞数及HIF-1α、VEGF、EPO蛋白和mRNA表达水平均显著增加(P<0.05),脑缺血半暗带区病理学改变均有所好转。结论电针“百会”“水沟”“足三里”“曲池”能激活HIF-1α-VEGF-EPO通路蛋白和基因表达,增加CD34阳性细胞数量,介导内皮细胞血管新生,从而提高MCAO大鼠rCBF,改善脑组织结构和功能,且治疗效果具有时间累积效应。 展开更多
关键词 脑缺血 血管新生 低氧诱导因子-1Α 血管内皮生长因子 促红细胞生成素 信号通路 电针
下载PDF
Transcriptomic and bioinformatics analysis of the mechanism by which erythropoietin promotes recovery from traumatic brain injury in mice
4
作者 Weilin Tan Jun Ma +9 位作者 Jiayuanyuan Fu Biying Wu Ziyu Zhu Xuekang Huang Mengran Du Chenrui Wu Ehab Balawi Qiang Zhou Jie Zhang Zhengbu Liao 《Neural Regeneration Research》 SCIE CAS CSCD 2024年第1期171-179,共9页
Recent studies have found that erythropoietin promotes the recovery of neurological function after traumatic brain injury.However,the precise mechanism of action remains unclea r.In this study,we induced moderate trau... Recent studies have found that erythropoietin promotes the recovery of neurological function after traumatic brain injury.However,the precise mechanism of action remains unclea r.In this study,we induced moderate traumatic brain injury in mice by intrape ritoneal injection of erythro poietin for 3 consecutive days.RNA sequencing detected a total of 4065 differentially expressed RNAs,including 1059 mRNAs,92 microRNAs,799 long non-coding RNAs,and 2115circular RNAs.Kyoto Encyclopedia of Genes and Genomes and Gene Ontology analyses revealed that the coding and non-coding RNAs that were differentially expressed after traumatic brain injury and treatment with erythropoietin play roles in the axon guidance pathway,Wnt pathway,and MAPK pathway.Constructing competing endogenous RNA networks showed that regulatory relationship between the differentially expressed non-coding RNAs and mRNAs.Because the axon guidance pathway was repeatedly enriched,the expression of Wnt5a and Ephb6,key factors in the axonal guidance pathway,was assessed.Ephb6 expression decreased and Wnt5a expression increased after traumatic brain injury,and these effects were reversed by treatment with erythro poietin.These findings suggest that erythro poietin can promote recove ry of nerve function after traumatic brain injury through the axon guidance pathway. 展开更多
关键词 axon guidance bioinformatics analysis competing endogenous RNA erythropoietin Gene Ontology Kyoto Encyclopedia of Genes and Genomes non-coding RNA RNA sequencing TRANSCRIPTOMICS traumatic brain injury
下载PDF
硼替佐米与沙利度胺方案分别联合rhEPO治疗多发性骨髓瘤的疗效及安全性分析
5
作者 邹昭玲 王小华 +1 位作者 陶盛能 程之明 《中国实验血液学杂志》 CSCD 北大核心 2024年第1期159-163,共5页
目的:探讨硼替佐米与沙利度胺方案分别联合重组人促红细胞生成素(rh EPO)治疗多发性骨髓瘤(MM)的疗效及安全性。方法:选择2013年1月-2018年12月于芜湖市第二人民医院就诊的80例MM患者为研究对象,采用简单随机法分为硼替佐米组(n=40)、... 目的:探讨硼替佐米与沙利度胺方案分别联合重组人促红细胞生成素(rh EPO)治疗多发性骨髓瘤(MM)的疗效及安全性。方法:选择2013年1月-2018年12月于芜湖市第二人民医院就诊的80例MM患者为研究对象,采用简单随机法分为硼替佐米组(n=40)、沙利度胺组(n=40)。硼替佐组给予硼替佐米方案联合rh EPO治疗,沙利度胺组给予沙利度胺方案联合rh EPO治疗,每3周为1个疗程,所有患者均治疗3个疗程。比较3个疗程后两组患者的临床疗效,以及治疗前与治疗3个疗程后两组患者的肿瘤相关生化指标[乳酸脱氢酶(LDH)、β2-微球蛋白(β2-MG)、血管内皮生长因子(VEGF)、凋亡抑制蛋白Survivin]、骨髓相关指标[血清M蛋白、骨髓浆细胞、血红蛋白(Hb)]及凝血功能指标[活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、纤溶酶原激活物抑制物(PAI)、循环中总微粒(TMPs)]表达水平的变化,并记录两组患者不良反应发生情况。结果:治疗3个疗程后,硼替佐米组ORR率(92.5%)高于沙利度胺组(90.0%),但差异无统计学意义(P>0.05);治疗3个疗程后,两组患者的LDH、β2-MG、VEGF、Survivin、血清M蛋白、骨髓浆细胞、APTT、PT、PAI、TMPs水平均明显低于治疗前,且硼替佐米组明显低于沙度利安组(P<0.05);治疗3个疗程后,两组患者Hb表达水平均明显高于治疗前,且硼替佐米组明显高于沙利度胺组(P<0.05)。治疗过程中,硼替佐米组不良反应发生率显著低于沙利度胺组(P<0.05)。结论:沙利度胺方案与硼替佐米方案分别联合rh EPO治疗MM的临床疗效相当,但硼替佐米方案联合rh EPO对MM患者肿瘤相关生化指标、骨髓相关指标及凝血状态改善效果更为突出。 展开更多
关键词 硼替佐米 沙利度胺 重组人促红细胞生成素 多发性骨髓瘤
下载PDF
EPO注射部位的改变对血液透析患者治疗效果的影响
6
作者 林燕兰 《中文科技期刊数据库(引文版)医药卫生》 2024年第5期0090-0093,共4页
探究促红细胞生成素(Erythropoietin,EPO)注射部位的改变对血液透析患者的临床治疗效果。方法 36例血液透析患者进组。研究时间为:2021年6月-2023年12月。随机分为2组(每组均有18例):对照组(在三角肌下注射EPO)、实验组(在肘关节伸侧部... 探究促红细胞生成素(Erythropoietin,EPO)注射部位的改变对血液透析患者的临床治疗效果。方法 36例血液透析患者进组。研究时间为:2021年6月-2023年12月。随机分为2组(每组均有18例):对照组(在三角肌下注射EPO)、实验组(在肘关节伸侧部区域注射EPO)。结果 治疗后,2组临床有关指标(如:其一,注射部位不良反应发生率;其二,疼痛评分;其三,临床治疗总有效率;其四,患者配合度;其五,CRP表达水平;其六,HB表达水平;其七,ALB表达水平;其八,SF等)比较为:P<0.05。结论 在肘关节伸侧部区域注射EPO可显著提高血液透析患者的临床治疗效果,与此同时不会增加患者的不良反应,提高患者的临床配合度以及改善血清有关指标等。 展开更多
关键词 epo 注射部位 血液透析 临床治疗效果
下载PDF
红细胞生成素简介(Erythropoietin.EPO) 被引量:8
7
作者 杜宝中 《西藏大学学报(社会科学版)》 2002年第3期31-34,共4页
红细胞生成素是机体生理条件下以及失血后调控红细胞生成的主要生长刺激因子,在机体红细胞生成中具有重要作用。本文对近年来红细胞生成素在来源、分子结构、信号传导机制、生物学作用及临床应用等方面的研究进行了简单概述。
关键词 红细胞生成素 来源 分子结构 信号传导机制 生物学作用 临床应用
下载PDF
EPO、IL-1β、MMP-9/TIMP-1与烧伤患者瘢痕评分、创面愈合时间关系及对创面愈合质量的预测价值 被引量:2
8
作者 王之学 肖继州 +2 位作者 于强 杨书培 郭延民 《中国美容医学》 CAS 2023年第4期12-16,共5页
目的:探讨促红细胞生成素(Erythropoietin,EPO)、白介素-1β(Interleukin-1β,IL-1β)、基质金属蛋白酶-9/基质金属蛋白酶抑制剂-1(Matrix metalloproteinase-9/Tissue inhibitor of metalloproteinase-1,MMP-9/TIMP-1)与烧伤患者瘢痕... 目的:探讨促红细胞生成素(Erythropoietin,EPO)、白介素-1β(Interleukin-1β,IL-1β)、基质金属蛋白酶-9/基质金属蛋白酶抑制剂-1(Matrix metalloproteinase-9/Tissue inhibitor of metalloproteinase-1,MMP-9/TIMP-1)与烧伤患者瘢痕评分、创面愈合时间关系及对创面愈合质量的预测价值。方法:选取2018年5月-2021年1月笔者科室收治的113例深Ⅱ度烧伤患者,采用削痂植皮联合外用重组人粒细胞-巨噬细胞刺激因子治疗,根据创面愈合质量分为良好组(n=88)、不良组(n=25),比较两组基线资料及治疗前、治疗5 d、10 d后EPO、IL-1β、MMP-9/TIMP-1,应用Pearson分析治疗5 d、10 d后EPO、IL-1β、MMP-9/TIMP-1与温哥华瘢痕量表(Vancouver scar scale,VSS)、创面愈合时间关系,采用多因素Logistic回归方程分析创面愈合质量的相关影响因素,采用受试者工作特征曲线(Receiver operating characteristic,ROC)及ROC下面积(Area under the curve,AUC)分析治疗5 d、10 d后EPO、IL-1β、MMP-9/TIMP-1,预测创面愈合质量价值。结果:不良组创面愈合时间、VSS评分数值均高于良好组(P<0.05);不良组治疗5 d、10 d后EPO低于良好组,IL-1β、MMP-9/TIMP-1高于良好组,差异均有统计学意义(P<0.05);治疗5 d、10 d后EPO与VSS评分、创面愈合时间呈负相关(P<0.05);治疗5 d、10 d后IL-1β、MMP-9/TIMP-1与VSS评分、创面愈合时间呈正相关(P<0.05);将创面愈合时间、VSS评分控制后,治疗5 d、10 d后EPO、IL-1β、MMP-9/TIMP-1仍与创面愈合质量相关(P<0.05);治疗10 d后EPO、IL-1β、MMP-9/TIMP-1的AUC大于治疗5 d后,且EPO、IL-1β联合MMP-9/TIMP-1的AUC大于任一单一指标。结论:EPO、IL-1β、MMP-9/TIMP-1与烧伤患者瘢痕评分、创面愈合时间、创面愈合质量有关,联合检测能为临床预测创面质量提供有效参考,并有望成为促进创面愈合、提高愈合质量的一个干预靶点。 展开更多
关键词 epo IL-1Β MMP-9/TIMP-1 烧伤 VSS评分 创面愈合时间 创面愈合质量
下载PDF
EPO对窒息诱导新生大鼠脑损伤和CoCl_(2)诱导人脑胶质瘤细胞系U251缺氧的改善作用
9
作者 呼格吉乐 王婷 苏慧敏 《山东医药》 CAS 2023年第9期46-51,共6页
目的观察促红细胞生成素(EPO)对窒息诱导新生大鼠脑损伤和CoCl_(2)诱导人脑胶质瘤细胞系U251缺氧的改善作用。方法①7日龄SPF级新生Wistar大鼠随机分为对照组、窒息组、EPO组,每组22只。窒息组和EPO组新生大鼠采用常压窒息法构建脑损伤... 目的观察促红细胞生成素(EPO)对窒息诱导新生大鼠脑损伤和CoCl_(2)诱导人脑胶质瘤细胞系U251缺氧的改善作用。方法①7日龄SPF级新生Wistar大鼠随机分为对照组、窒息组、EPO组,每组22只。窒息组和EPO组新生大鼠采用常压窒息法构建脑损伤模型。EPO组脑损伤模型大鼠腹腔注射5000 IU/(kg•d)的EPO,连续注射14 d;窒息组脑损伤模型大鼠注射等体积的生理盐水,连续注射14 d;对照组不注射生理盐水和EPO。每组取10只大鼠,采用Morris水迷宫实验观察各组新生大鼠空间记忆能力,包括逃避潜伏期、上台前游泳路程、90 s内穿越原平台次数、平台内运动距离、平台滞留时间、穿越有效区域次数、有效区域内运动距离和有效区域内滞留时间。采用旷场实验观察各组新生大鼠自主运动能力,包括运动总路程、中央区域路程和平均速度。每组取6只大鼠,连续干预第3天和第7天时断头处死,取大鼠大脑称重并计算脑组织含水量,采用速率法检测血清脑损伤标志物乳酸脱氢酶(LDH)。②人脑胶质瘤细胞系U251分为空白对照组、CoCl_(2)组、EPO组,CoCl_(2)组加入CoCl_(2)制备缺氧模型,EPO组加入CoCl_(2)和EPO,空白对照组加入等量培养液,继续培养24 h。采用CCK-8法测算各组细胞存活率,采用流式细胞术测算各组细胞凋亡率,采用比色法测算各组细胞上清液LDH。结果①与对照组比较,窒息组新生大鼠的逃避潜伏期、上台前游泳路程、干预第3天和第7天脑组织含水量及血清LDH水平显著升高(P均<0.05);与窒息组相比,EPO组新生大鼠的逃避潜伏期、上台前游泳路程、干预第3天和第7天脑组织含水量及血清LDH水平显著降低(P均<0.05)。与对照组比较,窒息组新生大鼠90 s内穿越原平台次数、平台内运动距离、平台滞留时间、穿越有效区域次数、有效区域内运动距离、有效区域内滞留时间、运动总路程、中央区域路程、平均速度均显著降低(P均<0.05);与窒息组相比,EPO组新生大鼠90 s内穿越原平台次数、平台内运动距离、平台滞留时间、穿越有效区域次数、有效区域内运动距离、有效区域内滞留时间、运动总路程、中央区域路程、平均速度均显著升高(P均<0.05)。②EPO组细胞存活率高于CoCl_(2)组(P<0.05),细胞凋亡率、细胞上清液LDH水平均低于CoCl_(2)组(P均<0.05)。结论EPO能够改善窒息后脑损伤大鼠的空间记忆能力、自主运动能力和脑水肿程度,改善脑损伤。EPO能够升高CoCl_(2)诱导的缺氧U251细胞存活率,降低细胞凋亡率和细胞上清液LDH水平。 展开更多
关键词 促红细胞生成素 颅脑损伤 缺氧性脑损伤 新生儿脑损伤 星形胶质细胞 乳酸脱氢酶
下载PDF
Erythropoietin Receptor Gene (EPOR) Polymorphisms are Associated with Sow Litter Sizes 被引量:1
10
作者 ZHANG Long-chao WANG Li-gang LI Yong YAN Hua ZHAO Ke-bin WANG Li-xian 《Agricultural Sciences in China》 CAS CSCD 2011年第6期931-937,共7页
The erythropoietin receptor (EPOR) has shown to play an important role in fetal survival by promoting the maturation of red blood cells in many studies of uterine capacity and litter size in swine. In this study, we... The erythropoietin receptor (EPOR) has shown to play an important role in fetal survival by promoting the maturation of red blood cells in many studies of uterine capacity and litter size in swine. In this study, we screened the porcine EPOR gene for mutations and identified five single nucleotide polymorphisms (SNPs): g.705G〉T in intron 1, g.2 373C〉T in intron 4, and g.2 882C〉T, g.3 035A〉G, and g.3 132A〉T in intron 6. We then genotyped 247 Beijing Black (BB) sows and compared the polymorphism data with the litter sizes of 1 375 parities among the sows. At first parity, there was no association of g.2 882C〉T and g.3 132A〉T with litter sizes. However, the CT sows in g.2 882C〉T had 2.13 higher total number born (TNB) (P〈0.01) and 1.81 higher number born alive (NBA) (P〈0.01) than the CC sows and the heterozygous sows in g.3 132A〉T had the highest litter size when compared to the two homozygotes for the later parities (P〈0.05). In the g.3 035A〉G SNP, for the later parities, the TNB of the sows with the GG genotype was 3.81 higher (P〈0.01) and the NBA was 2.75 higher (P〈0.01) than that with the AA genotype but no difference at first parity. The G allele of the EPOR g.705G〉T SNP was associated with a greater litter size at both the first parity (P〈0.05) and later parities (P〈0.01). Furthermore, we determined the allele frequencies for this SNP among five Chinese indigenous pig breeds (Erhualian, Laiwu Black, Meishan, Min, and Rongchang) and three western commercial pig breeds (Duroc, Landrace, and Large White). The G allele of the EPOR g.705G〉T SNP was significantly more common in the more prolific Chinese breeds. These results indicated that the EPOR could be an important candidate gene for litter size and g.705G〉T can serve as a useful genetic marker for improving litter size in both first and later parities in swine. 展开更多
关键词 erythropoietin receptor litter size PIG single nucleotide polymorphism
下载PDF
Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient:A case report 被引量:4
11
作者 Wei-Hong Yu Xie-Jia Li Fang Yuan 《World Journal of Clinical Cases》 SCIE 2020年第23期6048-6055,共8页
BACKGROUND Hyporesponsiveness to erythropoiesis-stimulating agents(ESAs)is a prevalent problem in patients with chronic kidney disease.It is associated with increased morbidity and mortality in patients who undergo di... BACKGROUND Hyporesponsiveness to erythropoiesis-stimulating agents(ESAs)is a prevalent problem in patients with chronic kidney disease.It is associated with increased morbidity and mortality in patients who undergo dialysis.A significant proportion of patients do not respond to iron supplementation and conventional ESAs.We report a case of severe ESA hyporesponsiveness-related anemia that was successfully treated with oral roxadustat.CASE SUMMARY A 59-year-old Chinese woman had high blood glucose for 25 years,maintenance hemodialysis for 7 years,and recurrent dizziness and fatigue for more than 2 years.Laboratory tests showed severe anemia(hemoglobin level of 54 g/L),though bone marrow biopsy,fluorescence in situ hybridization,and hemolysis tests were within normal ranges.We initially administered first-line therapies and other adjuvant treatments,such as blood transfusions,ESAs,and adequate dialysis,but the patient did not respond as anticipated.Her erythropoietinresistant anemia was probably not only due to chronic renal insufficiency.The patient received the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat(100 mg,three times weekly).After 12 wk of treatment,the patient’s hemoglobin increased significantly,and her symptoms were alleviated.During the follow-up period,adverse drug reactions were controllable and tolerable.CONCLUSION Oral roxadustat is effective and tolerable for the treatment of ESA hyporesponsiveness-related anemia in patients undergoing hemodialysis. 展开更多
关键词 Renal anemia erythropoietin hyporesponsiveness HEPCIDIN Interleukin 6 Roxadustat Case report
下载PDF
薄膜扩散梯度技术与紫外光谱法联合富集、检测rhEPO
12
作者 杨元义 《重庆科技学院学报(自然科学版)》 CAS 2023年第2期117-122,共6页
以EPO抗体修饰的Fe_(3)O_(4)粉末-聚丙烯酰胺凝胶为结合相,明胶凝胶为扩散层,通过薄膜扩散梯度技术(DGT)与紫外光谱法,对去离子水、人体尿液中的rhEPO进行富集和检测的实验研究。在25℃、常压环境下,DGT中结合相的饱和富集容量为0.0758... 以EPO抗体修饰的Fe_(3)O_(4)粉末-聚丙烯酰胺凝胶为结合相,明胶凝胶为扩散层,通过薄膜扩散梯度技术(DGT)与紫外光谱法,对去离子水、人体尿液中的rhEPO进行富集和检测的实验研究。在25℃、常压环境下,DGT中结合相的饱和富集容量为0.0758μg cm^(2),当pH值为5.5~8.0、无机盐浓度为0.3%~1.5%时,rhEPO的检测回收率基本不受影响。对质量浓度为6~15 ng mL的rhEPO水溶液进行检测时,rhEPO检测回收率的平均值为81.9%;对质量浓度为5~20 ng mL的rhEPO人体尿液进行检测时,rhEPO检测回收率的平均值为79.8%。 展开更多
关键词 薄膜扩散梯度技术 RHepo 紫外光谱法 rhepo富集 尿液样本
下载PDF
Hepc/25(OH)D3、EPO、sTfR-F与慢性肾衰竭MHD患者肾性贫血关系及联合预测并发感染的ROC分析
13
作者 张瑞 赵飞 +1 位作者 闫珍珍 马记磊 《医学检验与临床》 2023年第3期20-24,共5页
目的:探讨铁调素与维生素D3比值[Hepc/25(OH)D3]、促红细胞生成素(EPO)、可溶性转铁蛋白受体/铁指数(sTfR-F)与慢性肾衰竭维持性血液透析(MHD)患者肾性贫血的关系及联合预测并发感染的价值。方法:选取2018年1月-2020年12月我院139例慢... 目的:探讨铁调素与维生素D3比值[Hepc/25(OH)D3]、促红细胞生成素(EPO)、可溶性转铁蛋白受体/铁指数(sTfR-F)与慢性肾衰竭维持性血液透析(MHD)患者肾性贫血的关系及联合预测并发感染的价值。方法:选取2018年1月-2020年12月我院139例慢性肾衰竭MHD患者,根据透析1个月内是否并发感染分为感染组(n=32)、非感染组(n=107),比较两组Hepc/25(OH)D3、EPO、sTfR-F、血红蛋白(Hb)、转铁蛋白饱和度(TSAT)、血细胞比容(HCT),分析Hepc/25(OH)D3、EPO、sTfR-F与肾性贫血相关指标关系、感染相关影响因素及各指标预测感染的价值。结果:感染组Hepc/25(OH)D3、sTfR-F高于非感染组,EPO低于非感染组(P<0.05);感染组Hb、TSAT、HCT低于非感染组(P<0.05);Hepc/25(OH)D3、sTfR-F与Hb、TSAT、HCT呈负相关,EPO与Hb、TSAT、HCT呈正相关(P<0.05);Hepc/25(OH)D3、EPO、sTfR-F均为慢性肾衰竭MHD患者发生感染的影响因素(P<0.05);Hepc/25(OH)D3、EPO、sTfR-F预测慢性肾衰竭MHD患者并发感染的曲线下面积(AUC)分别为0.810、0.784、0.765,各指标联合预测的AUC最大,为0.864。结论:Hepc/25(OH)D3、EPO、sTfR-F与慢性肾衰竭MHD患者肾性贫血密切相关,且是感染发生的影响因素,各指标联合在预测感染发生方面具有较高应用价值。 展开更多
关键词 慢性肾衰竭 维持性血液透析 肾性贫血 铁调素与维生素D3比值 促红细胞生成素 可溶性转铁蛋白受体/铁指数
下载PDF
颅内动脉瘤夹闭术联合rHu-EPO、依达拉奉对动脉瘤性SAH患者氧化应激、神经损伤的影响 被引量:1
14
作者 罗泽鹏 罗忠平 +2 位作者 邬娜 邓人富 廖佐明 《临床和实验医学杂志》 2023年第2期179-183,共5页
目的探讨颅内动脉瘤夹闭术联合重组人促红细胞生成素(rHu-EPO)、依达拉奉对动脉瘤性蛛网膜下腔出血(SAH)的临床效果。方法采用前瞻性研究方法,选取2019年1月至2022年1月在中南大学湘雅医院治疗的动脉瘤性SAH患者78例,采用信封法将患者... 目的探讨颅内动脉瘤夹闭术联合重组人促红细胞生成素(rHu-EPO)、依达拉奉对动脉瘤性蛛网膜下腔出血(SAH)的临床效果。方法采用前瞻性研究方法,选取2019年1月至2022年1月在中南大学湘雅医院治疗的动脉瘤性SAH患者78例,采用信封法将患者随机分为观察组(n=39)和对照组(n=39)。对照组给予颅内动脉瘤夹闭术,观察组在对照组基础上联合rHu-EPO、依达拉奉治疗。观察两组手术前后脑氧供需、氧化应激、美国国立卫生院神经功能缺损评分(NIHSS)评分、简易智力状态检查量表(MMSE)评分、日常生活能力(ADL)及并发症发生情况。结果术后24 h,观察组的颈内静脉血氧饱和度(SjvO_(2))、颈内静脉血氧含量(CjvO_(2))、动脉血氧含量(CaO_(2))、颈内动-静脉血氧含量差(Ca-JvO_(2))和脑氧饱和度(rSO_(2))为(60.03±4.11)%、(9.20±1.21)%、(13.35±1.34)%、(5.03±0.97)%和(67.56±9.94)%,均明显高于对照组[(54.43±6.89)%、(8.03±1.15)%、(10.08±1.41)%、(4.36±0.91)%、(61.18±10.41)%],差异均有统计学意义(P<0.05)。术后24 h,观察组的超氧化物岐化酶(SOD)和过氧化氢酶(CAT)分别为(88.52±11.79)、(68.89±8.14)U/mL,均明显高于对照组[(79.92±12.15)、(62.29±8.03)U/mL],而丙二醛为(5.51±0.97)mmol/L,明显低于对照组[(6.02±0.91)mmol/L],差异均有统计学意义(P<0.05)。观察组术后1个月美国国立卫生院神经功能缺损评分(NIHSS)评分为(6.01±1.06)分,明显低于对照组[(7.25±1.03)分],而简易智力状态检查量表(MMSE)评分和日常生活能力(ADL)评分分别为(26.16±2.09)、(66.67±4.51)分,明显高于对照组[(25.20±1.91)、(60.09±5.22)分],差异均有统计学意义(P<0.05)。观察组的脑血管痉挛发生率为5.13%,明显低于对照组(20.51%),差异有统计学意义(P<0.05)。结论颅内动脉瘤夹闭术联合rHu-EPO、依达拉奉治疗动脉瘤性SAH患者有较好的效果,具有氧化应激反应轻、保护患者神经功能、改善脑氧供需平衡及脑氧饱和度等优点。 展开更多
关键词 颅内动脉瘤夹闭术 重组人促红细胞生成素 依达拉奉 动脉瘤性蛛网膜下腔出血
下载PDF
Erythropoietin inhibits ferroptosis and ameliorates neurological function after spinal cord injury 被引量:2
15
作者 Yu Kang Rui Zhu +4 位作者 Shuang Li Kun-Peng Qin Hao Tang Wen-Shan Shan Zong-Sheng Yin 《Neural Regeneration Research》 SCIE CAS CSCD 2023年第4期881-888,共8页
Ferroptosis is one of the critical pathological events in spinal cord injury.Erythropoietin has been reported to improve the recovery of spinal cord injury.However,whether ferroptosis is involved in the neuroprotectiv... Ferroptosis is one of the critical pathological events in spinal cord injury.Erythropoietin has been reported to improve the recovery of spinal cord injury.However,whether ferroptosis is involved in the neuroprotective effects of erythropoietin on spinal cord injury has not been examined.In this study,we established rat models of spinal cord injury by modified Allen’s method and intraperitoneally administered 1000 and 5000 IU/kg erythropoietin once a week for 2 successive weeks.Both low and high doses of erythropoietin promoted recovery of hindlimb function,and the high dose of erythropoietin led to better outcome.High dose of erythropoietin exhibited a stronger suppressive effect on ferroptosis relative to the low dose of erythropoietin.The effects of erythropoietin on inhibiting ferroptosis-related protein expression and restoring mitochondrial morphology were similar to those of Fer-1(a ferroptosis suppressor),and the effects of erythropoietin were largely diminished by RSL3(ferroptosis activator).In vitro experiments showed that erythropoietin inhibited RSL3-induced ferroptosis in PC12 cells and increased the expression of xCT and Gpx4.This suggests that xCT and Gpx4 are involved in the neuroprotective effects of erythropoietin on spinal cord injury.Our findings reveal the underlying anti-ferroptosis role of erythropoietin and provide a potential therapeutic strategy for treating spinal cord injury. 展开更多
关键词 erythropoietin ferroptosis Gpx4 iron overload lipid peroxidation mechanism neurological function recovery spinal cord injury spinal neuron xCT
下载PDF
Study of Immunoassay Methods for Recombinant Human Erythropoietin (rhEPO) Using Competitive ELISA
16
作者 JinYAN JieBoMI WenBaoCHANG 《Chinese Chemical Letters》 SCIE CAS CSCD 2004年第8期939-942,共4页
Two different immunoassay methods, competitive indirect enzyme-linked immuno-sorbent assay (CI-ELISA) and amplificative competitive indirect ELISA (ACI-ELISA) using biotin-avidin complex system were studied to detect ... Two different immunoassay methods, competitive indirect enzyme-linked immuno-sorbent assay (CI-ELISA) and amplificative competitive indirect ELISA (ACI-ELISA) using biotin-avidin complex system were studied to detect rhEPO. The linear ranges were 50-20000 ng/mL and 10-50000 ng/mL for CI-ELISA and ACI-ELISA, respectively. The low detection limits of CI-ELISA and ACI-ELISA were 62.8 ng/mL and 8.5 ng/mL, respectively. 展开更多
关键词 Recombinant human erythropoietin (rhepo) polyclonal antibody (pAb) competitive indirect ELISA (CI-ELISA) ampliflcative competitive indirect ELISA (ACI-ELISA).
下载PDF
重组人促红素致抗EPO抗体介导的纯红细胞再生障碍性贫血1例 被引量:1
17
作者 黄丽群 吕聪 +2 位作者 方俊海 卢光亮 黄小理 《中国药物应用与监测》 CAS 2023年第2期133-135,共3页
1例33岁男性患者,2021年1月起开始规律血液透析,同时因贫血(Hb 77 g·L^(−1))开始予重组人促红素注射液(EPO,10000 IU,qw,ih)治疗,2021年10月3日患者出现2次晕厥并摔倒,查Hb 49 g·L^(−1),予停用EPO,并予输注红细胞、补铁等对... 1例33岁男性患者,2021年1月起开始规律血液透析,同时因贫血(Hb 77 g·L^(−1))开始予重组人促红素注射液(EPO,10000 IU,qw,ih)治疗,2021年10月3日患者出现2次晕厥并摔倒,查Hb 49 g·L^(−1),予停用EPO,并予输注红细胞、补铁等对症治疗,患者Hb未见明显回升,2021年11月24日检测抗EPO抗体和抗EPO中和抗体均为阳性,诊断为抗EPO抗体介导的纯红细胞再生障碍性贫血,予免疫抑制剂联合罗沙司他治疗后Hb上升至114 g·L^(−1),患者停止输血。 展开更多
关键词 重组人促红素 罗沙司他 纯红细胞再生障碍性贫血 药品不良反应
下载PDF
Improved Recovery of Erythropoietin and Darbepoetin from Equine Plasma by the Application of a Wheat Germ Agglutinin Mediated Pre-Extraction Prior to Immunoaffinity Chromatography
18
作者 Shawn M. R. Stanley Danny Chua 《Advances in Bioscience and Biotechnology》 2014年第7期651-660,共10页
We describe a two-step method that uses wheat germ agglutinin immobilized on Sepharose gel followed by immunoaffinity chromatography (IAC) to extract recombinant human erythropoietin and Darbepoetin from equine plasma... We describe a two-step method that uses wheat germ agglutinin immobilized on Sepharose gel followed by immunoaffinity chromatography (IAC) to extract recombinant human erythropoietin and Darbepoetin from equine plasma. Lectin affinity chromatography was shown to be an effective approach for isolating these epoetins from plasma and in combination with IAC;this method gave superior recovery when compared to the use of the latter technique alone. Moreover, due to the ease with which it can be scaled up, it is particularly well suited for pre-concentrating larger volumes of samples prior to IAC and this provides a facile way of improving the overall sensitivity with which these foreign proteins can be detected in equine plasma. 展开更多
关键词 erythropoietin DARBepoETIN Alfa IMMUNOAFFINITY EXTRACTION Lectin Affinity EXTRACTION Wheat GERM AGGLUTININ Horseracing
下载PDF
Assessment of Patient Perceptions about Use of Wepox Pen<sup>TM</sup>(Recombinant Erythropoietin Delivery Device with 30,000 IU Cartridge) in the Management of Anemia in Chronic Kidney Disease Patients
19
作者 Hanmant Barkate Salman Motlekar +1 位作者 Sameer Rao Sanjay Kamble 《Open Journal of Nephrology》 2017年第2期38-46,共9页
Objective: To assess perceptions about ease of use and other benefits of Wepox PenTM (loaded with 30,000 IU cartridge of recombinant erythropoietin) in the management of anemia in adult chronic kidney disease (CKD) pa... Objective: To assess perceptions about ease of use and other benefits of Wepox PenTM (loaded with 30,000 IU cartridge of recombinant erythropoietin) in the management of anemia in adult chronic kidney disease (CKD) patients. Material and methods: In this prospective, observational, multicentric post marketing surveillance, adult CKD patients treated with erythropoietin were enrolled from November 2015 to December 2016 to understand their opinions about Wepox PenTM. Ease of use of pen, ease of administering accurate dose, confidence in administration and ease of storage and disposal of cartridge were assessed on five points Likert scale: 1. very easy;2. somewhat easy;3. neither easy nor difficult;4. somewhat difficult;5. very difficult. Global assessment was performed on five points scale: 1. excellent;2. very good;3. good;4. average;5. not good. Safety was recorded by checking pain and discomfort and adverse events. Results: A total of 263 patients (mean age 32.87 years;66% male;34% female) were enrolled. Number of patients reporting ease of use as “very easy” from 209 (80.7%) at baseline increased to 245 (94.6%) and 249 (96.1%) at visit 2 (p = 0.001) and visit 3 (p = 0.001) respectively. Number of “very easy” response for accurate dose increased from 236 (91.1%) at visit 1 to 246 (95%) at visit 2 (p = 0.84) and 249 (96.1%) at visit 3 (p = 0.001). Number of the patients with “no pain” at injection site increased from 177 (68.3%) at visit 1 to 205 (79.2%) and 212 (81.9%) at visit 2 (p = 0.001) and visit 3 (p = 0.001) respectively. Improvement in number of patients with “no hurt” at visit 2 (p = 0.538) and visit 3 (p = 0.286) was not statistically significant. Number of patients reporting “somewhat easy” to “very easy” confidence in self injection increased from 251 (96.9%) at visit 2 to 255 (98.5%) at visit 3. Number of patients reporting ease of storage and disposal of cartridge as “somewhat easy” to “very easy” increased from 254 (98.1%) at visit 2 to 256 (98.9%) at visit 3. According to the global assessment, 144 (56.3%) cases reported “excellent” response. “Very good” and “Good” responses were reported by 106 (41.4%) and 6 (2.3%) patients respectively. A total of 230 (98.7%) patients said that they would prefer to use erythropoietin pen device for further treatment too. Conclusion: Wepox PenTM(recombinant erythropoietin) is easy to use and does not cause significant pain or discomfort. Ability to self-administer recombinant erythropoietin with Wepox PenTM is a great advantage which can make a significant difference for both CKD patients and doctors. Storage and disposal of cartridge is also easy. 展开更多
关键词 ANEMIA Chronic Kidney Disease erythropoietin PEN DEVICE
下载PDF
Cell-Based Biological Markers for Blood-Enriching Chinese Herbs: Erythropoietin Production in HepG2 Cells and Nitric Oxide Release in Human Umbilical Vein Endothelial Cells (HUVECs)
20
作者 Hoi Yan Leung Kam Ming Ko 《Chinese Medicine》 2023年第2期57-67,共11页
Chinese tonifying herbs, which are classified into four functional categories (namely, Yang, Qi, Yin, Blood) are commonly used for restoring normal body function and the prevention of diseases. To explore cell-based b... Chinese tonifying herbs, which are classified into four functional categories (namely, Yang, Qi, Yin, Blood) are commonly used for restoring normal body function and the prevention of diseases. To explore cell-based biological markers for Blood-enriching Chinese herbs, we investigate the effect of 11 commonly used Blood-enriching herbs on erythropoietin (EPO) production in HepG2 cells. Herbs for nourishing Yin were tested for determining the specificity of Blood-enriching herbs in inducing EPO production. In addition, the effects of Blood-enriching herbs on nitric oxide (NO) production in both HepG2 cells and human umbilical vein endothelial cells (HUVECs) were also investigated. The results indicated that methanolic extracts of Blood-enriching herbs (but not Yin-nourishing herbs) showed characteristic pharmacological activity in inducing EPO production in HepG2 cells and NO release in HUVECs. The experimental findings, therefore, support the use of cell-based EPO production and NO release as biological markers for Blood-enriching Chinese tonifying herbs. 展开更多
关键词 Blood-Enriching Chinese Herbs erythropoietin Nitric Oxide
下载PDF
上一页 1 2 222 下一页 到第
使用帮助 返回顶部